Zarontin capsules

|Zarontin capsules

Drugs search, click the first letter of a drug name:

| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 1 | 2 | 3 | 4 | 5 | 6 | 8 | 9  Home


Generic Name: ethosuximide
Dosage Form: Capsules

Zarontin Description

Zarontin (ethosuximide) is an anticonvulsant succinimide, chemically designated as alpha-ethyl-alpha-methyl-succinimide, with the following structural formula:

Each Zarontin capsule contains 250 mg ethosuximide, USP. Also contains: polyethylene glycol 400, NF. The capsule contains D&C yellow No. 10; FD&C red No. 3; gelatin, NF; glycerin, USP; and sorbitol.

Zarontin - Clinical Pharmacology

Ethosuximide suppresses the paroxysmal three cycle per second spike and wave activity associated with lapses of consciousness which is common in absence (petit mal) seizures. The frequency of epileptiform attacks is reduced, apparently by depression of the motor cortex and elevation of the threshold of the central nervous system to convulsive stimuli.

Indications and Usage for Zarontin

Zarontin is indicated for the control of absence (petit mal) epilepsy.


Ethosuximide should not be used in patients with a history of hypersensitivity to succinimides.


Blood dyscrasias, including some with fatal outcome, have been reported to be associated with the use of ethosuximide; therefore, periodic blood counts should be performed. Should signs and/or symptoms of infection (eg, sore throat, fever) develop, blood counts should be considered at that point.

Ethosuximide is capable of producing morphological and functional changes in the animal liver. In humans, abnormal liver and renal function studies have been reported.

Ethosuximide should be administered with extreme caution to patients with known liver or renal disease. Periodic urinalysis and liver function studies are advised for all patients receiving the drug.

Cases of systemic lupus erythematosus have been reported with the use of ethosuximide. The physician should be alert to this possibility.

Usage in Pregnancy

Reports suggest an association between the use of anticonvulsant drugs by women with epilepsy and an elevated incidence of birth defects in children born to these women. Data are more extensive with respect to phenytoin and phenobarbital, but these are also the most commonly prescribed anticonvulsants; less systematic or anecdotal reports suggest a possible similar association with the use of all known anticonvulsant drugs.

The reports suggesting an elevated incidence of birth defects in children of drug-treated epileptic women cannot be regarded as adequate to prove a definite cause and effect relationship. There are intrinsic methodological problems in obtaining adequate data on drug teratogenicity in humans; the possibility also exists that other factors, eg, genetic factors or the epileptic condition itself, may be more important than drug therapy in leading to birth defects. The great majority of mothers on anticonvulsant medication deliver normal infants. It is important to note that anticonvulsant drugs should not be discontinued in patients in whom the drug is administered to prevent major seizures because of the strong possibility of precipitating status epilepticus with attendant hypoxia and threat to life. In individual cases where the severity and frequency of the seizure disorder are such that the removal of medication does not pose a serious threat to the patient, discontinuation of the drug may be considered prior to and during pregnancy, although it cannot be said with any confidence that even minor seizures do not pose some hazard to the developing embryo or fetus.

The prescribing physician will wish to weigh these considerations in treating or counseling epileptic women of childbearing potential.



Ethosuximide, when used alone in mixed types of epilepsy, may increase the frequency of grand mal seizures in some patients.

As with other anticonvulsants, it is important to proceed slowly when increasing or decreasing dosage, as well as when adding or eliminating other medication. Abrupt withdrawal of anticonvulsant medication may precipitate absence (petit mal) status.

Information for Patients

Ethosuximide may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks, such as driving a motor vehicle or other such activity requiring alertness; therefore, the patient should be cautioned accordingly.

Patients taking ethosuximide should be advised of the importance of adhering strictly to the prescribed dosage regimen.

Patients should be instructed to promptly contact their physician if they develop signs and/or symptoms (eg, sore throat, fever), suggesting an infection.

Drug Interactions

Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).



Pediatric Use

Safety and effectiveness in pediatric patients below the age of 3 years have not been established. (See DOSAGE AND ADMINISTRATION section.)

Adverse Reactions

Gastrointestinal System: Gastrointestinal symptoms occur frequently and include anorexia, vague gastric upset, nausea and vomiting, cramps, epigastric and abdominal pain, weight loss, and diarrhea. There have been reports of gum hypertrophy and swelling of the tongue.

Hemopoietic System: Hemopoietic complications associated with the administration of ethosuximide have included leukopenia, agranulocytosis, pancytopenia, with or without bone marrow suppression, and eosinophilia.

Nervous System: Neurologic and sensory reactions reported during therapy with ethosuximide have included drowsiness, headache, dizziness, euphoria, hiccups, irritability, hyperactivity, lethargy, fatigue, and ataxia. Psychiatric or psychological aberrations associated with ethosuximide administration have included disturbances of sleep, night terrors, inability to concentrate, and aggressiveness. These effects may be noted particularly in patients who have previously exhibited psychological abnormalities. There have been rare reports of paranoid psychosis, increased libido, and increased state of depression with overt suicidal intentions.

Integumentary System: Dermatologic manifestations which have occurred with the administration of ethosuximide have included urticaria, Stevens-Johnson syndrome, systemic lupus erythematosus, pruritic erythematous rashes, and hirsutism.

Special Senses: Myopia.

Genitourinary System: Vaginal bleeding, microscopic hematuria.


Acute overdoses may produce nausea, vomiting, and CNS depression including coma with respiratory depression. A relationship between ethosuximide toxicity and its plasma levels has not been established. The therapeutic range of serum levels is 40 mcg/mL to 100 mcg/mL, although levels as high as 150 mcg/mL have been reported without signs of toxicity.


Treatment should include emesis (unless the patient is or could rapidly become obtunded, comatose, or convulsing) or gastric lavage, activated charcoal, cathartics, and general supportive measures. Hemodialysis may be useful to treat ethosuximide overdose. Forced diuresis and exchange transfusions are ineffective.

Zarontin Dosage and Administration

Zarontin is administered by the oral route. The initial dose for patients 3 to 6 years of age is one capsule (250 mg) per day; for patients 6 years of age and older, 2 capsules (500 mg) per day. The dose thereafter must be individualized according to the patient"s response. Dosage should be increased by small increments. One useful method is to increase the daily dose by 250 mg every four to seven days until control is achieved with minimal side effects. Dosages exceeding 1.5 g daily, in divided doses, should be administered only under the strictest supervision of the physician. The optimal dose for most pediatric patients is 20 mg/kg/day. This dose has given average plasma levels within the accepted therapeutic range of 40 to 100 mcg/mL. Subsequent dose schedules can be based on effectiveness and plasma level determinations.

Zarontin may be administered in combination with other anticonvulsants when other forms of epilepsy coexist with absence (petit mal). The optimal dose for most pediatric patients is 20mg/kg/day.

How is Zarontin Supplied

Zarontin is supplied as:
N 0071-0237-24—Bottles of 100. Each capsule contains 250 mg ethosuximide.

Store at 25°C (77°F); excursions permitted to 15–30°C (59–86°F) [see USP Controlled Room Temperature].

Zarontin is also supplied as:
N 0071-2418-23—1 pint bottles. Each 5 mL of syrup contains 250 mg ethosuximide in a raspberry flavored base.

Rx only

Manufactured by:
R.P. Scherer North America
St. Petersburg, FL 33716 USA


August 2006

Zarontin (Ethosuximide)
Product Code 0071-0237 Dosage Form CAPSULE
Route Of Administration ORAL DEA Schedule
Name (Active Moiety) Type Strength
Ethosuximide (Ethosuximide) Active 250 MILLIGRAM  In 1 CAPSULE
polyethylene glycol 400 Inactive  
D&C yellow No. 10 Inactive  
FD&C red No. 3 Inactive  
gelatin Inactive  
glycerin Inactive  
sorbitol Inactive  
Characteristic Appearance Characteristic Appearance
Color ORANGE Score 1
Shape CAPSULE Symbol false
Imprint Code P-D;237 Coating false
Size 8mm
# NDC Package Description Multilevel Packaging
1 0071-0237-24 100 CAPSULE In 1 BOTTLE None

Revised: 10/2006

Where can I get more information about Zarontin capsules ? We recommend to use

Typical mistypes for Zarontin capsules
xarontin capsules, sarontin capsules, aarontin capsules, zzrontin capsules, zsrontin capsules, zwrontin capsules, zqrontin capsules, zaeontin capsules, zadontin capsules, zafontin capsules, zatontin capsules, za5ontin capsules, za4ontin capsules, zarintin capsules, zarkntin capsules, zarlntin capsules, zarpntin capsules, zar0ntin capsules, zar9ntin capsules, zarobtin capsules, zaromtin capsules, zarojtin capsules, zarohtin capsules, zaronrin capsules, zaronfin capsules, zarongin capsules, zaronyin capsules, zaron6in capsules, zaron5in capsules, zarontun capsules, zarontjn capsules, zarontkn capsules, zaronton capsules, zaront9n capsules, zaront8n capsules, zarontib capsules, zarontim capsules, zarontij capsules, zarontih capsules, zarontin xapsules, zarontin vapsules, zarontin fapsules, zarontin dapsules, zarontin czpsules, zarontin cspsules, zarontin cwpsules, zarontin cqpsules, zarontin caosules, zarontin calsules, zarontin ca-sules, zarontin ca0sules, zarontin capaules, zarontin capzules, zarontin capxules, zarontin capdules, zarontin capeules, zarontin capwules, zarontin capsyles, zarontin capshles, zarontin capsjles, zarontin capsiles, zarontin caps8les, zarontin caps7les, zarontin capsukes, zarontin capsupes, zarontin capsuoes, zarontin capsulws, zarontin capsulss, zarontin capsulds, zarontin capsulrs, zarontin capsul4s, zarontin capsul3s, zarontin capsulea, zarontin capsulez, zarontin capsulex, zarontin capsuled, zarontin capsulee, zarontin capsulew, arontin capsules, zrontin capsules, zaontin capsules, zarntin capsules, zarotin capsules, zaronin capsules, zarontn capsules, zaronti capsules, zarontincapsules, zarontin apsules, zarontin cpsules, zarontin casules, zarontin capules, zarontin capsles, zarontin capsues, zarontin capsuls, zarontin capsule, azrontin capsules, zraontin capsules, zaorntin capsules, zarnotin capsules, zarotnin capsules, zaronitn capsules, zarontni capsules, zaronti ncapsules, zarontinc apsules, zarontin acpsules, zarontin cpasules, zarontin caspules, zarontin capusles, zarontin capslues, zarontin capsuels, zarontin capsulse, zzarontin capsules, zaarontin capsules, zarrontin capsules, zaroontin capsules, zaronntin capsules, zaronttin capsules, zarontiin capsules, zarontinn capsules, zarontin capsules, zarontin ccapsules, zarontin caapsules, zarontin cappsules, zarontin capssules, zarontin capsuules, zarontin capsulles, zarontin capsulees, zarontin capsuless, etc.

© Copyright by 2001-2019. All rights reserved